Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Implantica AG
IMP-A-SDBImplantica AG engages in the research and distribution of medical implants in Switzerland. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a remote controlled artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for the treatment of aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein. Address: Aeulestrasse 45, Vaduz, Liechtenstein, 9490
Analytics
Precio Objetivo de WallStreet
591.88 SEKRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave IMP-A-SDB
Análisis de dividendos IMP-A-SDB
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout IMP-A-SDB
Valoración de la acción IMP-A-SDB
Finanzas IMP-A-SDB
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |